Accelerated Drug Resistance Screening With An Enhanced, Mutagenic Base Editor Platform
Time: 11:30 am
day: Day 1 Track A AM
Details:
- Accurate prediction of cis or trans drug resistant mutations could enable unique single agent or compound treatment approaches to improve response durability
- Widely used methods to screen for cancer drug resistance mutations in vitro are inefficient or provide an incomplete view
- An enhanced mutagenic base editor system was developed to validate known and discover new mutations arising in response to select anti-cancer molecules
